Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL28533203 | 0.98 | TSHR (0.50) | TSHRCYP1A2BRD4KDM4EALDH1A1 | |
| SCHEMBL719806 | 0.83 | ALDH1A1 (0.55) | TSHRKDM4EALDH1A1LMNANPC1 | |
| SCHEMBL4921789 | 0.81 | CYP1A2 (0.46) | TSHRCYP1A2KDM4EALDH1A1CA12 | |
| SCHEMBL12457581 | 0.81 | CYP1A2 (0.46) | TSHRCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL30555050 | 0.80 | CYP1A2 (0.42) | TSHRCYP1A2BRD4KDM4EALDH1A1 | |
| SCHEMBL16651751 | 0.80 | CYP1A2 (0.42) | TSHRCYP1A2BRD4KDM4EALDH1A1 | |
| SCHEMBL28891861 | 0.80 | TSHR (0.58) | TSHRCYP1A2KDM4EALDH1A1HSD17B10 | |
| Cytosine SCHEMBL29277994 | 0.80 | CDC7 (0.45) | TSHRCYP1A2BRD4KDM4EALDH1A1 | |
| SCHEMBL12523424 | 0.79 | CYP1A2 (0.44) | TSHRCYP1A2KDM4EALDH1A1CA12 | |
| SCHEMBL12396913 | 0.79 | CYP1A2 (0.49) | TSHRCYP1A2KDM4EALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107033204-A | The pyrimidine of 5 modifications and their purposes | 私募蛋白质体公司 | 2017-08-11 | — | — | CN | claimed |
| CN-102985435-A | 5-position modified pyrimidines and their use | SOMALOGIC INC | 2013-03-20 | — | — | CN | claimed |
| EP-4326274-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| CN-115209952-B | Substituted pyrazolopyrimidines and use thereof | 维基分析有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20240208994-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117756848-A | TH-302 derivative and preparation method thereof | 常州大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-115003303-B | PRMT5 inhibitors | 默沙东公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4326274-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117396469-A | Inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| EP-1398384-A1 | Enhanced production of taxanes by cell cultures of taxus species | Phyton Inc. (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6376490-B1 | STRONG N-METHYL-D-ASPARATE RECEPTOR ANTAGONISTS; USEFUL IN TREATING STROKES, ISCHEMIA, AND CENTRAL NERVOUS SYSTEM INJURIES | PFIZER INC | 2002-04-23 | — | — | US | disclosed |
| EP-0885212-B1 | QUINOXALINEDIONES | PFIZER RES AND BR DEV COMPANY (IE) | 2001-11-14 | — | — | EP | disclosed |
| EP-0927169-A1 | 4-CYCLOALKYL-5-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS CROP PROTECTION AGENTS | ZENECA LIMITED (GB) | 1999-07-07 | — | — | EP | disclosed |
| EP-0885212-A1 | QUINOXALINEDIONES | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998011074-A1 | 4-CYCLOALKYL-5-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS CROP PROTECTION AGENTS | ZENECA LIMITED (GB) | 1998-03-19 | — | — | WO | disclosed |
| US-5707930-A | HERBICIDES, AGRICULTURE | ZENECA LIMITED (GB) | 1998-01-13 | — | — | US | disclosed |
| WO-1997032873-A1 | QUINOXALINEDIONES | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-09-12 | — | — | WO | disclosed |
| EP-0018139-A2 | Pyrido (2,3-d) pyrimidine derivatives, pharmaceutical compositions containing them and processes for preparing the pyrido (2,3-d) pyrimidine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208994-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | TSHR 3639/4885CYP1A2 2976/4885BRD4 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.